Armand Butera

Over 21 million children and adolescents aged 12–20 years had received 1 or more doses of a COVID-19 vaccine, amounting to 1 reported case of MIS-C per million vaccinated individuals in this age group.

the high prevalence of the condition in middle-age and elderly populations has led to frequent updates on the long-term efficacy of current therapies and new investigational agents.

Investigators review the current understanding of the role of the BTK pathway and the potential value of pharmacological inhibition of BTK as a therapeutic strategy.

Telemedicine use has become more prevalent during the ongoing COVID-19 pandemic. However, there is limited data on patient satisfaction with tele-dermatology

The safety syringe and auto-injector provide patients with psoriasis with 2 options for the self-administration of bimekizumab.

Dupilumab did not reach statistical significance in interim analysis despite numeric improvements being observed across key endpoints.

Prior to the ISS, there was no known scale to measure ichthyosis severity across the entire body.

Dr. Chovatiya returns to speak of some of the changes regarding the study of skin of color that have occurred in recent years.

Data pooled from 5 trials show a consistent and manageable safety profile for continued treatment with PALFORZIA.

Previous research indicated that the worsening of different inflammatory cutaneous diseases had been associated with exposure to air pollution.

Despite this, alexithymia was significantly associated with impaired quality of life and increased stigmatization levels in young students with acne.

Data showed that the greatest improvement before and after acne care was achieved after medical treatment by a dermatologist.

Dr. Yeung and colleagues offer insights into treating transmasculine patients who develop acne after gender-affirming testosterone therapy

Dr. Yan noted that increased public awareness among patients and health care providers was essential for earlier detection of melanoma.

More than half of dermatology practices have separated in recent years, which has influenced how skin of color and other areas of dermatology study are taught across the United States.

Dr. Lal speaks to deficiencies in dermatology education as they relate to skin of color, and how more inclusive language and media help dermatologists improve patient care.

The program has returned with a renewed focus for Black and skin of color-dominant residency programs in addition to those with limited access to mentorship resources.

Dr. Shankar speaks to how physician training and patient conversations can evolve in dermatology through progressive antiracism efforts.

Previous studies reported that skin and soft tissue infections were common among persons experiencing homelessness.

Dr. Lipner says that primary investigators and sub-investigators can advocate for the diversification of clinical trial participants.

People with skin of color are often presumed to suffer fewer negative effects from solar radiation, making the importance of photoprotection in this population understudied and underestimated.

If approved, dupilumab will be the first biologic medicine available in the US to treat uncontrolled moderate-to-severe atopic dermatitis for young children 6 months to 5 years old.

Investigators detailed personally mediated, institutional, and internalized antiracism practices that could be applicable to medicine.

Practice separation is occurring more frequently in medium- and large-sized practice groups and among early- and late-career dermatologists.

Patients with asthma and bronchiectasis were more likely to have chronic rhinosinusitis than patients without bronchiectasis, according to investigators.

Cases of the inflammatory heart event occurred 1626 times after an mRNA vaccine dose in US patients from December 2020 to August 2021.

Investigators believe the data highlighted the importance of improving and maintaining adequate sleep duration as a public health target for obesity prevention.

New data from the ECZTRA 6 trial noted improvements in itch, sleep interference, anxiety and more.

The recent FDA approval of the oral JAK inhibitor could change the landscape of atopic dermatitis management.